Naproxen or Loratadine for bone pain associated with Pegfilgrastim treatment for Breast Cancer patients stages I, II or III.
Participants must be newly diagnosed, no prior chemotherapy, and have at least four (4) cycles of chemotherapy planned (but they can not be weekly treatments).
Exclusions include, but are not limited to: Another cancer within the past five (5) years, current chronic pain, bleeding disorders, chronic use of NSAIDS or steroids, prior use of G-CSF or chemotherapy.
Clinical Trial #A221102:
Testosterone versus placebo subcutaneously 2x for post menopausal women who are receiving Anastrozole or Letrozole and have side effects causing pain 5 or greater out of a scale of 10.
ER and PR status would both have to be positive with at least a 30% positivity.
BMI required to be between 18-32 kg/m2.
Clinical Trial #B-43:
Radiation with or without Herceptin after surgery for women with Her 2 positive Ductal Carcinoma in situ.
Participants can have Ductal Carcinoma in situ and Lobular Carcinoma in situ, but not invasive. Lumpectomy surgery only. Participation must begin prior to the 120th day from surgery.
Exclusions include, but are not limited to: Contralateral breast cancer, multicentric disease, partial breast radiation, active cardiac disease, uncontrolled blood pressure, history of CHF, cardiomyopathy or a recent MI.
Clinical Trial E-1Z11:
Lab study for post menopausal women who are currently on Anastrozole (Arimidex).
Patients who areStage I-III who are ER and/or PR positive and have completed adjuvant chemotherapy may qualify.
Exclusions include, but are not limited to those who have chronic analgesic use, have had a DVT or PE in the last five years and have a pain score of four or higher out of ten.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”